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Introduction
Two hallmarks of testis morphogenesis are seminifer-
ous cord formation and testis-specific vascular develop-
ment. The first step in seminiferous cord formation is the 
expression of Sry from the Sertoli cell which occurs be-
tween embryonic days 10.5 and 12.5 (E10.5 and 12.5) 
in the mouse (Hacker et al. 1995). Expression of Sry pro-
motes the expression of Sertoli cell-specific genes, such 
as Sox9 (Kidokoro et al. 2004), which then stimulate the 
proliferation of Sertoli cells and aggregation of Sertoli and 
primordial germ cells (McLaren 1991, Capel et al. 1999). 
The next step in seminiferous cord formation involves the 
migration of cells from the mesonephros into the develop-
ing testis and the resulting formation of cords and testis-
specific vasculature. These events occur around E11.5–
12.5 in the mouse (Tilmann & Capel 1999, Brennan et al. 
2002). Distinct, male-specific vasculature which includes 
the large coelomic vessel develops concurrently with 
seminiferous cord formation, and is evident in the mouse 
testis by E12.5 (Brennan et al. 2002). In the rat, seminifer-
ous cords begin to develop at E13.5 (Magre & Jost 1980, 
Jost et al. 1981), a continuous basal lamina which sur-
rounds and delineates cords first appears at E14.5 (Magre 
& Jost 1991), and this basal lamina is found throughout 
the rat testis by E15.5 (Magre & Jost 1991). 
Sertoli cells within the developing testis are thought 
to drive the migration of mesonephric cells by producing 
paracrine growth factors which act as chemoattractants 
(Martineau et al. 1997). Culturing E11.5 mouse gonads 
separate from mesonephroi impairs cord development 
(Buehr et al. 1993), suggesting that mesonephric cell mi-
gration is crucial to proper cord formation. It has been 
proposed that these migrating cells are endothelial and 
pre-peritubular cells (Merchant-Larios et al. 1993); how-
ever, other studies have suggested that only cells which 
are positive for endothelial cell markers migrate from 
the mesonephros into the XY gonad (Cool et al. 2008, 
Combes et al. 2009). Previous studies in our laboratory 
have demonstrated that vascular endothelial growth fac-
tor A (VEGFA) plays a role in both angiogenesis and sem-
iniferous cord formation in the developing testis. Treat-
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Abstract
Vascular endothelial growth factor A (VEGFA) plays a role in both angiogenesis and seminiferous cord formation, and alternative 
splicing of the Vegfa gene produces both proangiogenic isoforms and antiangiogenic isoforms (B-isoforms). The objectives of this 
study were to evaluate the expression of pro- and antiangiogenic isoforms during testis development and to determine the role of 
VEGFA isoforms in testis morphogenesis. Quantitative RT-PCR determined that Vegfa_165b mRNA was most abundant between em-
bryonic days 13.5 and 16 (E13.5 and 16; P < 0.05). Compared with ovarian mRNA levels, Vegfa_120 was more abundant at E13–14 
(P < 0.05), Vegfa_164 was less abundant at E13 (P < 0.05), and Vegfa_165b tended to be less abundant at E13 (P < 0.09) in testes. Im-
munohistochemical staining localized antiangiogenic isoforms to subsets of germ cells at E14–16, and western blot analysis revealed 
similar protein levels for VEGFA_165B, VEGFA_189B, and VEGFA_206B at this time point. Treatment of E13 organ culture testes with 
VEGFA_120, VEGFA_164, and an antibody to antiangiogenic isoforms (anti-VEGFAxxxB) resulted in less organized and defined semi-
niferous cords compared with paired controls. In addition, 50 ng/ml VEGFA_120 and VEGFA_164 treatments increased vascular den-
sity in cultured testes by 60 and 48% respectively, and treatment with VEGFAxxxB antibody increased vascular density by 76% in tes-
tes (0.5 ng/ml) and 81% in ovaries (5 ng/ml) compared with controls (P < 0.05). In conclusion, both pro- and antiangiogenic VEGFA 
isoforms are involved in the development of vasculature and seminiferous cords in rat testes, and differential expression of these iso-
forms may be important for normal gonadal development. 
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ment with VEGFA antagonists or VEGFA receptor signal 
transduction inhibitors reduced vascular density and per-
turbed, or totally inhibited, cord formation in E13 rat or-
gan culture testes (Bott et al. 2006). 
The Vegfa gene consists of eight exons separated by 
seven introns. Alternative splicing of the Vegfa gene pro-
duces different mRNA splice variants and, thus, differ-
ent protein isoforms with varying numbers of amino ac-
ids. Rodent VEGFA isoforms have one less amino acid 
per isoform than human VEGFA, and each isoform has 
unique functions depending on its composition and dif-
fusion properties (Park et al. 1993, Ferrara et al. 2003). 
Differences in diffusion allow VEGFA isoforms to form 
a chemoattractant gradient, promoting the migration of 
endothelial cells for neovascularization in developing 
organs or tumors (Grunstein et al. 2000, Springer et al. 
2000). 
All VEGFA isoforms were once thought to be proangio-
genic; however, antiangiogenic isoforms have now been 
identified. The antiangiogenic isoform, VEGFA_165B, was 
first discovered in human renal cells (Bates et al. 2002), 
and it has been proposed that every proangiogenic iso-
form has a corresponding antiangiogenic isoform where 
exon 8a is substituted by 8b (Woolard et al. 2004). Our 
laboratory recently identified and sequenced mRNA for 
antiangiogenic isoforms (Vegfa_165b and Vegfa_189b) in 
rat ovaries, and through these sequences, it determined 
that these rat antiangiogenic isoforms (VEGFA_165B and 
VEGFA_189B) have an additional amino acid residue 
compared with their respective proangiogenic isoforms 
(VEGFA_164 and VEGFA_188; Artac et al. 2009). 
It has been shown that human VEGFA_165B binds 
with the same affinity as VEGFA_165 to kinase insert do-
main protein receptor (KDR, also known as VEGFR2 and 
FLK1) but does not allow for subsequent activation of 
signaling pathways. Additionally, VEGFA_165B inhibits 
VEGFA_165-mediated angiogenesis, and VEGFA_165B-
expressing tumors grow more slowly than VEGFA_165-
expressing tumors (Woolard et al. 2004). Therefore, it ap-
pears that the antiangiogenic VEGFA isoforms may inhibit 
the actions of the proangiogenic isoforms by blocking 
their binding to the VEGFA receptors, KDR and FMS-like 
tyrosine kinase 1 (FLT1, also known as VEGFR1). 
We have previously localized VEGFA expression to 
Sertoli and germ cells, and demonstrated Vegfa_120, 
Vegfa_164, and Vegfa_188 mRNA expression in devel-
oping testes (Bott et al. 2006). The first objective of the 
current study was to identify the expression of the antian-
giogenic isoforms and to further evaluate the expression 
patterns of the proangiogenic isoforms during testis devel-
opment. The second objective of this study was to inves-
tigate the role of VEGFA isoforms in testis morphogenesis. 
Specifically, we sought to compare the effects of treat-
ment with proangiogenic VEGFA isoforms and neutraliza-
tion of antiangiogenic VEGFA isoforms on vascular devel-
opment and cord formation. 
Results
Vegfa isoform mRNA expression during testis 
development 
Conventional RT-PCR was used to evaluate Vegfa an-
tiangiogenic isoform mRNA expression in developing rat 
testes. Five developmental time points were evaluated 
(E13, E14, E16, E18, and postnatal day 0 (P0)). There was 
no detectable expression of Vegfa_165b prior to cord for-
mation (E13) but Vegfa_165b was present after cord for-
mation at E14, E16, E18, and P0. 
Quantitative RT-PCR (QRT-PCR) was performed on 
seven developmental time points (E13, E13.5, E14, E16, 
E18, P0, and P3) during testis development to deter-
mine mRNA abundance for Vegfa_120, Vegfa_164, and 
Vegfa_165b. Levels for Vegfa_120 mRNA decreased from 
E13 to E16 (P < 0.02), increased from E16 to E18 (P < 0.04), 
decreased from E18 to P0 (P < 0.04), and then increased 
from P0 to P3 (P < 0.0001; Figure 1A). mRNA levels for 
Vegfa_164 increased from E13 to E13.5–14 (P < 0.05), in-
creased from E14 to E16 (P < 0.003), decreased from E16 
to E18–P0 (P < 0.002), and then decreased again from 
E18–P0 to P3 (P < 0.03; Figure 1B). Levels for Vegfa_165b 
mRNA were greater at E13.5, E14, and E16 compared with 
all other time points analyzed (Figure 1C; P < 0.05). 
We then compared mRNA levels for Vegfa_120, 
Vegfa_164, and Vegfa_165b between testes and ovaries 
at E13 and E14 to pinpoint any differences in Vegfa iso-
forms at the developmental time point when endothelial 
cells are migrating from the mesonephros to establish vas-
culature, and seminiferous cords are forming in the devel-
oping testis. No cell migration occurs in the ovary at these 
time points. The ovarian data used for this comparison 
were taken from previously published QRT-PCR studies 
from our laboratory (Artac et al. 2009, McFee et al. 2009). 
The same primers, probes, and conditions were used for 
each isoform in both the testis and ovarian experiments. 
mRNA levels for Vegfa_120 were significantly lower in 
ovaries than in testes at both E13 (P < 0.0001) and E14 (P 
< 0.03; Figure 2A). At E13, Vegfa_164 mRNA levels were 
greater in ovaries than in testes (P < 0.05); however, there 
was no difference in levels at E14 (Figure 2B). Levels for 
Vegfa_165b mRNA tended to be greater in ovaries than 
in testes at E13 (P < 0.09) but there was no difference be-
tween testes and ovaries at E14 (Figure 2C). 
Western blot analysis of VEGFA isoforms during testis 
development
Western blot analysis was used to evaluate the 
presence of VEGFA isoforms in developing rat tes-
tes. Five developmental time points were evaluated: 
E13, E16, E18, P0, and P4 (Figure 3A). The primary an-
tibody that was used for these western blots will de-
tect all VEGFA isoforms, including antiangiogenic 
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isoforms. Consequently, the bands detected for 
VEGFA_120, VEGFA_164, VEGFA_188, and VEGFA_205 
may also contain the similarly sized antiangiogenic iso-
forms: VEGFA_121B, VEGFA_165B, VEGFA_189B, and 
VEGFA_206B respectively. Quantitative analysis dem-
onstrated that VEGFA_120/121B was greater in abun-
dance than VEGFA_164/165B, VEGFA_188/189B, and 
VEGFA_205/206B at E18 (P < 0.02; data not shown). The 
abundance of VEGFA_205/206B was greater at P4 than 
that at E13–E16 (P < 0.05; Figure 3E). Additionally, the 
values for VEGFA_188/189B tended to be greater at P4 
than the values at E13–E16 (P < 0.09; Figure 3D). No sta-
tistical differences were detected among isoforms at E13, 
E16, P0, and P4 or in the abundance of VEGFA_120/121B 
(Figure 3B) and VEGFA_164/165B (Figure 3C) across de-
velopmental ages. 
A second western blot was performed using an an-
tibody made to the region of exon 8b to evaluate the 
presence of only the VEGFA antiangiogenic isoforms in 
E13–P4 rat testes (Figure 4A). Protein bands consistent 
with VEGFA_121B, VEGFA_165B, VEGFA_189B, and 
VEGFA_206B were present. Although Vegfa_165b and 
Vegfa_189b have been previously recognized in rats via 
RT-PCR (Artac et al. 2009) and VEGFA_121B has been 
isolated in human tissues (Rennel et al. 2009), this is the 
first time that the antiangiogenic isoform, VEGFA_206B, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Quantitative RT-PCR for Vegfa_120 (A), Vegfa_164 (B), and 
Vegfa_165b (C) from E13 through P3 of testis development. Gapdh 
was used as an endogenous control to account for differences in 
starting material. These data are the result of at least three different 
pools of each age tissue. The mean ± s.e.m. normalized QRT-PCR 
values are presented for each developmental age. Developmen-
tal ages are labeled with letters to represent statistical comparisons: 
ages labeled with a common letter are not different while ages with-
out a common letter are significantly different (P < 0.05). 
Figure 2. Comparison of quantitative RT-PCR values between E13 
and E14 testes and ovaries for Vegfa_120 (A), Vegfa_164 (B), and 
Vegfa_165b (C). Gapdh was used as an endogenous control to ac-
count for differences in starting material. These data are the result of 
at least three different pools of each age tissue. The mean ± s.e.m. 
normalized QRT-PCR values are presented for each developmental 
age. Asterisks represent a statistically significant difference between 
testes and ovaries at each age (*P < 0.0001, **P < 0.05). The plus 
sign indicates a tendency toward different means (+P < 0.09). 
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has been identified. Quantification of bands revealed 
that VEGFA_165B was more abundant at P0 than 
VEGFA_189B (P < 0.04; data not shown). No statisti-
cal differences were detected among isoforms at any of 
the other developmental time points evaluated (data not 
shown). The abundance of VEGFA_189B was greater at 
P4 than the abundance at E16–18 (P < 0.04; Figure 4D). 
There were no statistical differences in the abundance of 
VEGFA_121B (Figure 4B), VEGFA_165B (Figure 4C), and 
VEGFA_206B (Figure 4E) across all ages evaluated, likely 
due to the high variation in protein levels across individ-
ual samples. 
Localization of VEGFA antiangiogenic isoforms within 
developing testes
Immunohistochemistry was performed on E14, E16, 
and P0 rat testes to localize the expression of antiangio-
genic VEGFA isoforms to specific cell types and tissue lo-
cations (Figure 5). At E14 (Figure 5B) and E16 (Figure 5C), 
the expression of antiangiogenic isoforms was detected in 
some, but not all, germ cells. Positive staining was also 
present within the mesonephros (Figure 5C). In P0 testes, 
high intensity staining was present within the interstitium 
with faint, or no staining was visible in Sertoli and germ 
cells (Figure 5D). No staining was identified in testis sec-
tions that were processed without primary antibody (Fig-
ure 5A). 
Effects of recombinant VEGFA_120 and VEGFA_164 on 
rat testis organ cultures
Treatment of E13 testis organ cultures with 50 ng/ml 
of recombinant VEGFA_120 (Figure 6D) or VEGFA_164 
(Figure 6G) perturbed seminiferous cord formation in the 
majority of treated testes based on visual evaluation of 
brightfield images of whole cultured organs. The cords in 
treated testes were undefined and poorly organized com-
pared with the cords in control testes (Figure 6A). Nei-
ther the depth (determined by the total number of Z-se-
ries confocal microscopy images taken of each organ) nor 
the area of testes treated with VEGFA_120 or VEGFA_164 
was significantly different from control testes (data not 
shown). The vascular density within VEGFA_120 (Figure 
6E and F) and VEGFA_164 (Figure 6H and I) treated tes-
tes was 60% (Figure 7A; P < 0.03) and 48% (Figure 7A; P 
< 0.05) greater respectively compared with controls (Fig-
ure 6B and C). 
Effects of VEGFAxxxB antibody on rat testis organ 
cultures
The seminiferous cords in the majority of testes treated 
with 0.5 ng/ml (Figure 6J) and 5 ng/ml (Figure 6M) of 
VEGFAxxxB antibody were also less defined and orga-
nized than the cords in control testes (Figure 6A). There 
was no difference in depth or area between testes treated 
Figure 3. (A) Western blot analysis for VEGFA isoforms 
from E13 to P4 of testis development. Black lines indi-
cate where different blot images have been spliced to-
gether. Recombinant VEGFA_164 served as a positive 
control (data not shown). Quantitative analysis of western 
blot bands for VEGFA_120/121B (B), VEGFA_164/165B 
(C), VEGFA_188/189B (D), and VEGFA_205/206B (E) 
based upon a standard curve created from recombinant 
VEGFA_164. These data are the result of at least three dif-
ferent pools of each age tissue. The mean ± s.e.m. densi-
tometry values are presented for each developmental age. 
Developmental ages are labeled with letters to represent 
statistical comparisons: ages labeled with a common letter 
are not different while ages without a common letter are 
significantly different (P < 0.05). 
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with either dose of the VEGFAxxxB antibody and testes 
treated with nonspecific IgG (data not shown). The vascu-
lar density of testes treated with 0.5 ng/ml of VEGFAxxxB 
antibody (Figure 6K and L) was increased by 76% (Fig-
ure 7; P < 0.008) compared with controls (Figure 6B and 
C). The vascular density of testes treated with the 5 ng/ml 
dose of VEGFAxxxB antibody (Figure 6N and O) tended 
to be different than controls (Figure 6B and C) but was not 
significantly different due to a high variation among sam-
ples (Figure 7; P < 0.09). 
Discussion
The current study is the first to report a role for both 
proangiogenic and antiangiogenic VEGFA isoforms in the 
regulation of vasculature and seminiferous cords in the 
developing rat testis. Neutralization of antiangiogenic iso-
forms through the use of a VEGFAxxxB antibody resulted 
in an increase in vascular density, suggesting that removal 
of antiangiogenic VEGFA isoforms is a powerful method 
to regulate vascular development. Furthermore, an imbal-
ance in the production of VEGFA pro- versus antiangio-
genic isoforms may severely impair testis morphology and 
development. 
Our laboratory has previously demonstrated the pres-
ence of Vegfa proangiogenic isoform mRNA expression 
during testis development (Bott et al. 2006), and in this 
study, we quantified Vegfa_120 and Vegfa_164 mRNA 
across the same developmental ages. mRNA levels for 
Vegfa_120 in the testis decreased from E13–13.5 to E14–
16, while VEGFA_120 protein was the most abundant iso-
form in embryonic testes after E13. The VEGFA_120 iso-
form is highly diffusible and is believed to be primarily 
involved in the recruitment of endothelial cells (Grunstein 
et al. 2000). During testis development, endothelial cells, 
resulting from the breakdown of mesonephric vascula-
ture, migrate into the testis and reaggregate to form the 
coelomic vessel. During this process, these endothelial 
cells only migrate between the regions where cords are 
forming, further establishing testis-specific vascular pat-
terns (Coveney et al. 2008). The decrease in abundance 
of Vegfa_120 mRNA after E13–13.5 is likely due to a re-
duced requirement for VEGFA_120 after mesonephric en-
dothelial cell migration. 
mRNA abundance for Vegfa_164 was greatest at E16 in 
the testis. The VEGFA_164 isoform is responsible for re-
cruiting endothelial cells and promoting the formation of 
major blood vessels (Grunstein et al. 2000, Ferrara et al. 
2003). The developing XY gonad recruits endothelial cells 
from the adjacent mesonephros. These migrating endo-
thelial cells contribute to the formation of the arterial sys-
tem within the testis, establishing a new pattern of blood 
flow (Brennan et al. 2002). It has been demonstrated that 
the proliferation of Sertoli cells increases dramatically af-
ter E14, and there is extensive proliferation of germ cells 
Figure 4. (A) Western blot analysis for antiangiogenic VEGFA 
isoforms from E13 to P4 of testis development. Recombinant 
VEGFA_165B served as a positive control (data not shown). 
Quantitative analysis of western blot bands for VEGFA_121B 
(B), VEGFA_165B (C), VEGFA_189B (D), and VEGFA_206B 
(E) based upon a standard curve created from recombinant 
VEGFA_165B. These data are the result of at least three dif-
ferent pools of each age tissue. The mean ± s.e.m. densi-
tometry values are presented for each developmental age. 
Developmental ages are labeled with letters to represent sta-
tistical comparisons: ages labeled with a common letter are 
not different while ages without a common letter are signifi-
cantly different (P < 0.05). 
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between E14 and E18 in the developing rat testis (Levine 
et al. 2000). Therefore, increased expression of Vegfa_164 
may be important in promoting increased blood flow and 
nutrients to the growing testis, or VEGFA_164 may have a 
more direct role in supporting the proliferation of Sertoli 
and/or germ cells. 
Levels for Vegfa_165b mRNA were greatest between 
E13.5 and E16 in the testis. An increase in the expression 
of the antiangiogenic Vegfa_165b may prevent excessive 
activity of proangiogenic isoforms, thus, preventing hyper-
vascularization or other detrimental effects on the devel-
oping testis. For example, treatment of E13 organ culture 
testes with recombinant VEGFA_120 and VEGFA_164 for 
3 days in the current study resulted in increased vascular 
density and disruption of cord formation. 
The Vegfa_120 mRNA isoform was more abundant in 
the testis at both E13 (just before seminiferous cord for-
mation) and E14 (just after cord formation). Quantification 
of our western blots revealed that VEGFA_120/121B was 
more abundant than VEGFA_164/165B, VEGFA188/189B, 
and VEGFA_205/206B at E16–18. The VEGFA_120 iso-
form is believed to play a role in endothelial cell recruit-
ment (Grunstein et al. 2000), and the migration of meso-
nephric endothelial cells and the formation of a distinct 
vascular pattern which occurs in the testis do not oc-
cur in the ovary. Instead, ovarian vascular development 
results from the proliferation and extension of pre-exist-
ing gonadal endothelial cells and vessels (Coveney et al. 
2008). Taken together, this suggests that VEGFA_120 may 
not only be critical for mesonephric endothelial cell mi-
gration and the formation of a sex-specific vasculature in 
the testis but may also be involved with the development 
of seminiferous cords. 
mRNA levels for Vegfa_165b tended to be greater in 
the ovary than in the testis at E13. Less expression of 
Vegfa_165b and thus, reduced inhibition of proangiogenic 
isoforms in the testis may help to promote endothelial cell 
migration and coelomic vessel formation. Additionally, in 
our western blotting experiments, VEGFA_165B was the 
most abundant antiangiogenic isoform in the testis from 
E18 to P3. This implies that the VEGFA_165B isoform is 
the predominant antiangiogenic isoform in the develop-
ing testis involved in the regulation of the angiogenic or 
possibly even nonangiogenic effects of the proangiogenic 
VEGFA isoforms. 
Our QRT-PCR and western blotting experiments re-
sulted in varied abundance patterns between the mRNA 
and protein for the different VEGFA isoforms. Even though 
the cause for these discrepancies is not clear, it may be 
the result of differences in posttranscriptional processing, 
and our laboratory is investigating this issue further. 
Protein for antiangiogenic VEGFA isoforms was local-
ized to the subsets of germ cells in E14–16 testes but little 
to no antiangiogenic VEGFA protein was present within 
seminiferous cords after birth. Other laboratories have 
demonstrated that treatment with proangiogenic VEGFA 
isoforms increases germ cell proliferation and survival in 
bovine testis explants (Caires et al. 2009). Therefore, the 
subset of germ cells expressing antiangiogenic VEGFA in 
embryonic testes may be apoptotic germ cells. The stain-
ing for antiangiogenic VEGFA isoforms in the embryonic 
testis was localized to the nucleus of the germ cells. Pre-
vious studies have localized VEGFA staining to the cyto-
plasm of rodent testicular cells (Nalbandian et al. 2003, 
Bott et al. 2006) and to what appears to be the nucleus of 
mitotically active bovine germ cells (Caires et al. 2009). 
Figure 5. (A) E14 testis sec-
tions with no primary antibody 
served as negative controls.  
Immunohistochemistry for 
VEGFA antiangiogenic isoforms 
in E14 (B), E16 (C), and P0 (D) 
testes. D was counterstained 
with hemotoxylin.  These data 
are the result of at least three 
different testes from each de-
velopmental time point. Scale 
bar represents 50 μm. T, tes-
tis; M, mesonephros; c, semi-
niferous cord; g, germ cell; i, 
interstitium. 
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The localization of antiangiogenic VEGFA to the nucleus 
of germ cells in this study is intriguing, and warrants fur-
ther investigation. If antiangiogenic VEGFA isoforms are 
associated with apoptotic germ cells, cellular compromise 
or nuclear fragmentation may allow for the nuclear bind-
ing of these isoforms. Our lab has also shown that VEGFA 
is expressed in germ cell cytoplasm and Sertoli cells from 
E14 through P5, and that KDR is present in Sertoli and 
germ cells at P0 and P5 (Bott et al. 2006). Previous studies 
have shown that there is a decrease in germ cell prolifera-
tion between E14 and P0 followed by an increase in pro-
liferation between P0 and P5 (Levine et al. 2000). Taken 
together, these data suggest that interactions between pro- 
and antiangiogenic VEGFA isoforms may have in role in 
germ cell proliferation and/or maturation. 
Organ culture testes treated with recombinant 
VEGFA_120 and VEGFA_164 developed intense vascu-
larization between seminiferous cords, had thick coelo-
mic vessels, and had greater vascular density compared 
with controls. Other studies have demonstrated that over-
expression of VEGFA isoforms leads to infertility in mice. 
Transgenic mice that overexpress VEGFA_165 in the testis 
and epididymis showed complete infertility (Korpelainen 
et al. 1998), while mice that overexpress VEGFA_120 had 
reduced or complete infertility due to impaired spermio-
genesis (Huminiecki et al. 2001). In the current study, the 
disruption of normal seminiferous cord formation may be 
due to the increased vascularization. 
Organ culture testes treated with VEGFAxxxB antibody 
also developed intense vascularization and perturbed 
Figure 6. Embryonic day 13 testis or-
gan cultures without treatment (A–C) or 
treatment with 50 ng/ml of recombinant 
VEGFA_120 (D–F), 50 ng/ml of recombi-
nant VEGFA_164 (G–I), 0.5 ng/ml of VEG-
FAxxxB antibody (J–L), and 5 ng/ml of 
VEGFAxxxB antibody (M–O). (A, D, G, J, 
and M) Brightfield images. (B, C, E, F, H, I, 
K, L, N, and O) Confocal images of whole 
mount immunohistochemistry staining for 
PECAM1 (red indicates endothelial cell 
marker) to localize vasculature. Scale bar 
represents 200 μm. T, testis; M, mesoneph-
ros; c, cord. 
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cord formation. The VEGFAxxxB antibody binds the an-
tiangiogenic VEGFA ‘B’ isoforms, preventing them from 
blocking proangiogenic isoforms from binding to their 
receptors. Binding of antiangiogenic isoforms to VEG-
FAxxxB antibody should therefore allow the endogenous 
VEGFA proangiogenic isoforms to act at their receptors to 
increase endothelial cell migration and proliferation. 
The results from the current study, along with those 
from previous studies (Bott et al. 2006), support a role 
for VEGFA in testis morphogenesis and vascular develop-
ment. This study also demonstrated that antiangiogenic 
VEGFA isoforms are critical during early testis morpho-
genesis. mRNA for Vegfa_120 is more abundant in the 
testis, while Vegfa_164 and Vegfa_165b are more abun-
dant in the ovary during the time when endothelial cells 
are migrating into the testis and testis-specific vascula-
ture is developing. Furthermore, the expression of antian-
giogenic VEGFA isoforms in germ cells in the embryonic 
testis suggests that the antiangiogenic isoforms may play 
a role in germ cell maturation. While organ culture tes-
tes treated with both proangiogenic isoforms and an an-
tiangiogenic isoforms antibody resulted in hypervascular-
ization and perturbed cord formation, treatment with the 
VEGFAxxxB antibody resulted in the greatest increase in 
vascular density. In conclusion, both pro- and antiangio-
genic isoforms play a role in the development of rat tes-
tes, and differential expression of these isoforms may be 
critical for normal gonadal development. 
Materials and Methods
Animals
Embryonic and postnatal ovaries were obtained from our 
own Sprague–Dawley rat colony at the University of Ne-
braska–Lincoln Animal Science Department, with founders 
purchased from Charles River (Wilmington, MA, USA). Testes 
were dissected from E13 to P3 rats in order to evaluate testes 
shortly before, during, and after seminiferous cord formation 
and testis-specific vascular development. To verify the sex of 
rat embryos utilized prior to morphological sex determina-
tion, Sry PCR was performed on genomic DNA according to 
previously reported methods (Anway et al. 2005). Embryonic 
age was calculated using plug date as E0. Postnatal age was 
determined using day of birth as P0. All animal procedures 
were approved by the University of Nebraska Animal Care 
and Use Committee. 
Vegfa isoforms RT-PCR and QRT-PCR 
Testes were dissected from rats at different ages, and me-
sonephroi were removed if present. Total RNA from these 
testes was isolated and converted to cDNA for subsequent 
RT-PCR according to standard protocols in our laboratory 
(McFee et al. 2009). The forward primer utilized for Vegfa 
antiangiogenic isoform conventional RT-PCR has been pre-
viously used for Vegfa proangiogenic (McFee et al. 2009) 
and antiangiogenic (Artac et al. 2009) isoform RT-PCR, and 
the reverse primer has been previously used for Vegfa anti-
angiogenic isoform RT-PCR (Artac et al. 2009). These prim-
ers were used with an annealing temperature of 54.5 °C for 
35 cycles to generate a 220-bp product for Vegfa_165b. The 
constitutively expressed gene, Gapdh, was used as a con-
trol for RNA isolation and amplification (Wesolowski et al. 
2003), and previously reported methods (McFee et al. 2009) 
were utilized to produce a 460-bp product. All PCR products 
were subcloned and confirmed using restriction digest anal-
ysis. PCR products were subcloned into pCRII (Invitrogen) 
using the TOPO TA Cloning kit (Invitrogen) and sequenced 
with primers for the T7 promoter region (data not shown). 
QRT-PCR primers and probes for rat Vegfa_120 (McFee et 
al. 2009), Vegfa_164 (McFee et al. 2009), and Vegfa_165b 
(Artac et al. 2009) have been used in prior experiments in 
our laboratory. Experimental and Gapdh PCRs were carried 
out in separate wells in triplicate. An arbitrary value of tem-
plate was assigned to the highest standard and corresponding 
values to the subsequent dilutions. These relative values are 
plotted against the threshold value for each dilution to gen-
erate a standard curve. The relative amount for each experi-
mental and Gapdh triplicate was assigned an arbitrary value 
based on the slope and y-intercept of the standard curve. The 
average of the experimental triplicate is divided by the aver-
Figure 7. Effect of VEGFA_120, VEGFA_164, 0.5 ng/ml VEGFAxxxB 
antibody, and 5 ng/ml VEGFAxxxB antibody on vascular density in 
cultured testes expressed as a percentage of control organs. Data are 
the result of 21 (A (VEGFA_120 and VEGFA_164)), 24 (A (0.5 ng/ml 
VEGFAxxxB antibody)), and 22 (A (5 ng/ml VEGFAxxxB antibody)) 
testis pairs. The mean ± s.e.m. stained areas for PECAM1 (vascu-
lar density) are presented for each organ culture treatment. Asterisks 
represent a statistically significant difference between treated and 
control groups (*P < 0.008, **P < 0.05). The plus sign indicates a 
tendency toward different means (+P < 0.09). Ab, antibody. 
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age of the Gapdh triplicate, and the resulting normalized val-
ues are used for statistical analysis (McFee et al. 2009). RT-
PCR and QRT-PCR were conducted on 3–5 different pools of 
tissue samples for each developmental time point. 
Protein extraction and western blotting for VEGFA 
isoforms
Testes were collected from rats at different ages (if pres-
ent, mesonephroi were removed), snap frozen in liquid ni-
trogen, and stored at −80 °C. Tissues were homogenized 
in a glass tissue grinder by mixing four organs with 60 μl of 
homogenization buffer: 50 mM Tris–HCl, pH 7.4, 150 mM 
NaCl, 10 mM EDTA, 0.1% SDS, 100 mM phenylmethane-
sulfonyl fluoride, 1:50 Protease Inhibitor cocktail (Sigma–Al-
drich), 1.5% Triton X-100, and 2 μM dl-dithiothreitol. The 
tissue and buffer mixture was centrifuged for 10 min at 4 °C, 
and the supernatant was collected, aliquoted, and stored at 
−80 °C. Protein samples (28 μg protein: proangiogenic, 15 
or 50 μg protein: antiangiogenic) were mixed with 12.5-μl 
sample buffer (62.5 mM Tris–HCl, pH 6.8, 20% glycerol, 2% 
SDS, 5% β-mercaptoethanol, trace Orange G) and enough 
Millipore water to bring total mixture volume to 40 μl. Sam-
ples were then incubated at 95 °C for 5 min and loaded onto 
12 or 15% polyacrylamide separating gels for electrophore-
sis. We utilized the higher concentration gels for three of our 
antiangiogenic western blots to provide better separation of 
the VEGFA isoforms. Pre-stained protein standards (Bio-Rad) 
were utilized to verify transfer efficiency and to approximate 
protein molecular weight. 
Proteins were electrotransferred onto polyvinylidene fluo-
ride membranes (Immobilon transfer membranes; Millipore, 
Billerica, MA, USA) with a semi-dry blotting apparatus (Bio-
Rad). Prior to transfer, the gel was soaked in transfer buffer 
(48 mM Tris–HCl, 39 mM glycine, 0.0375% SDS, and 20% 
methanol) twice for 10 min, the blotting paper (Bio-Rad) was 
soaked in transfer buffer for 5 min, and the membrane was 
soaked in 20% methanol for 2–3 min. After transfer, the mem-
brane was blocked with Odyssey blocking buffer (LI-COR Bio-
sciences, Lincoln, NE, USA) for 2 h at room temperature, and 
then incubated overnight with primary antibody at 4 °C with 
gentle shaking. After incubation with the primary antibody, the 
membrane was washed three times for 10 min at room tem-
perature in Tris-buffered saline with Tween (TBST) wash solu-
tion. The membrane was then incubated for 1 h with the sec-
ondary antibody at room temperature with gentle shaking. 
This and all subsequent steps were carried out without expos-
ing the membrane to light. After incubation with the second-
ary antibody, the membrane received three additional 10-min 
washes in TBST at room temperature. 
The VEGFA primary antibody was a goat polyclonal IgG 
raised against an epitope mapping at the N-terminus of 
mouse VEGFA (catalog number: sc-1836; Santa Cruz Bio-
technology, Santa Cruz, CA, USA). The VEGFA antiangio-
genic isoforms primary antibody was a mouse monoclonal 
IgG1 raised against a peptide corresponding to the 9-amino 
acid C-terminus of human VEGFA_165B (catalog number: 
ab14994; Abcam, Cambridge, MA, USA). This antibody 
has been characterized previously to bind VEGFA_165B 
(Woolard et al. 2004) and VEGFA_121B (Rennel et al. 
2009), and may also bind VEGFA_145B, VEGFA_183B, 
and VEGFA_189B (Perrin et al. 2005). Therefore, this anti-
body is collectively termed VEGFAxxxB but is sold commer-
cially (Abcam and R&D Systems, Minneapolis, MN, USA) as 
a VEGFA_165B antibody. The secondary antibodies utilized 
were Alexa Fluor 680 rabbit anti-goat IgG (Invitrogen) and 
IRDye 680 goat anti-mouse IgG (LI-COR Biosciences). The 
VEGFA primary antibody was diluted 1:100, the VEGFAxxxB 
antibody was diluted 1:1000, and the secondary antibodies 
were diluted 1:6000 in blocking buffer. Recombinant mouse 
VEGFA_164 and VEGFA_165B (R&D Systems) were utilized 
as loading controls for VEGFA antibody and VEGFAxxxB an-
tibody blots respectively. 
Images of blots were acquired with the Odyssey infrared 
imaging system, and the Odyssey software program (LI-COR 
Biosciences) was utilized for quantitative analysis. For each 
individual blot, a standard curve was established from the 
densitometry measurement of the recombinant protein load-
ing control, and the densitometry values of the VEGFA bands 
were quantified using this standard curve. Since different 
quantities of protein samples were utilized for the antiangio-
genic western blots, densitometry values were proportionally 
adjusted by the amount of sample protein used to allow for 
standardized comparison of values. Quantification of each 
VEGFA isoform was performed on 3–6 blots from each de-
velopmental time point. 
Immunohistochemistry for VEGFA antiangiogenic 
isoforms
Testes were histologically prepared, and immunohisto-
chemistry was performed according to the standard pro-
tocols in our laboratory (McFee et al. 2009). The primary 
antibody was a VEGFAxxxB antibody (Abcam, the same anti-
body used for western blotting). As a negative control, serial 
sections were processed without primary antibody. The bi-
otinylated goat anti-mouse secondary antibody was diluted 
1:300. The secondary antibody was detected with amino-
ethyl carbazole chromagen substrate solution (Zymed Labo-
ratories, South San Francisco, CA, USA). Immunohistochem-
istry was performed on at least three different sections of 
tissue from each age group. 
Organ cultures
Testes with attached mesonephroi from E13 rats were cul-
tured in accordance with previously reported organ culture 
methods (Bott et al. 2006). We cultured E13 gonads and me-
sonephroi from embryos with 15–18 tail somites since this 
stage of embryonic testis development immediately precedes 
mesonephric cell migration and seminiferous cord formation 
(Hacker et al. 1995, Uzumcu et al. 2002, Bott et al. 2008) 
and similar culture methods have demonstrated that control 
testes will develop cords and testis-specific vasculature with 
3 days of culture (Bott et al. 2006). One testis from each an-
imal was designated as a control, while its pair was treated 
with either 50 ng/ml of recombinant VEGFA_120 (R&D Sys-
tems), 50 ng/ml of recombinant VEGFA_164 (R&D Systems), 
5 ng/ml of VEGFAxxxB antibody, or 50 ng/ml of VEGFAxxxB 
antibody (Abcam, the same antibody utilized for western 
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blotting and immunohistochemistry). Doses of VEGFA_120, 
VEGFA_164, and VEGFAxxxB antibody (each diluted in PBS 
with 0.1% BSA) were added directly to the culture medium 
of the treated wells at the start of culture, and treatment was 
repeated daily. Similar doses of PBS with 0.1% BSA were 
added to the paired control wells for the VEGFA_120 and 
VEGFA_164 cultures, while nonspecific IgG in PBS with 
0.1% BSA was added to the paired control wells for the VEG-
FAxxxB antibody cultures. Culture media were changed ev-
ery other day. Only organ pairs in which control testes 
formed cords were used for analysis. All control testes in the 
VEGFA_164 (32 out of 32) and 0.5 ng/ml VEGFAxxxB anti-
body (25 out of 25) experiments formed cords, and all con-
trol testes but one in the VEGFA_120 (24 out of 25) and 5 ng/
ml VEGFAxxxB antibody (21 out of 22) experiments formed 
cords by the end of culture. 
Imaging and area analysis of organ cultures
After culture treatment, gonads were imaged to obtain 
individual testis area as previously described (McFee et al. 
2009). The area for each testis was measured three times, 
and these three areas were averaged to obtain an accurate 
area measurement. The mean area for each control organ 
was set to 100%, and the mean of each treated organ was 
calculated as a percentage of its paired control. A total of 17 
(5 ng/ml VEGFAxxxB antibody), 18 (0.5 ng/ml VEGFAxxxB 
antibody), and 20 (VEGFA_120 and VEGFA_164) testis pairs 
were imaged for area measurements. 
Whole mount immunohistochemistry of organ cultures 
and vascular density quantification
After imaging, gonads were fixed in 4% paraformalde-
hyde for whole mount immunohistochemistry. Whole mount 
immunohistochemistry for PECAM1 utilized a mouse mono-
clonal IgG1 primary antibody raised against rat platelet en-
dothelial cell adhesion molecule (BD Pharmingen, San Di-
ego, CA, USA) and followed the same procedures used for 
our previously reported VEGFA antagonist (V1) treated ovary 
culture experiments (McFee et al. 2009). Confocal micros-
copy was performed, and the PECAM1 density was evaluated 
for control and treated organ culture gonads as previously de-
scribed (McFee et al. 2009). Merged (all confocal z-section 
images merged together) red channel confocal images were 
used to analyze the PECAM1 density, and the vascular den-
sity or staining index was quantified using the National Insti-
tutes of Health Scion Image program (Scion Image, Frederick, 
MD, USA). Densitometry was performed on three, non-over-
lapping fields for each organ using a digital zoom at three 
times the original image that was acquired at 100× magnifica-
tion. Within each field, the staining index was defined as the 
number of pixels exceeding an arbitrary grey scale value. The 
mean staining index for each testis was defined as the average 
of the staining indexes from all three fields. The mean den-
sity for each control testis was set to 100%, and the mean of 
each treated testis was calculated as a percentage of its paired 
control. A total of 20 (VEGFA_120), 21 (5 ng/ml VEGFAxxxB 
antibody), 24 (0.5 ng/ml VEGFAxxxB antibody), and 27 
(VEGFA_164) testis pairs were analyzed for PECAM1 density. 
In the embryonic gonad, PECAM1 is a marker for both 
vascular endothelial cells and primordial germ cells; how-
ever, localization of PECAM1 expression to germ cells dimin-
ishes after the morphological differentiation of male and fe-
male gonads (Wakayama et al. 2003). Visual analysis of the 
confocal images did not reveal any apparent differences be-
tween the PECAM1-positive germ cells in treated testes and 
those in their paired controls; however, there were obvious 
differences in vasculature across organ pairs. Therefore, any 
variation in PECAM1 density for treated organ compared 
with controls was considered to be primarily the result of 
changes in vascular density. 
Statistical analysis
All data were analyzed by one-way ANOVA using JMP 
software (SAS Institute, Cary, NC, USA). Student’s t-test was 
used to compare mean normalized QRT-PCR values between 
different developmental ages and to compare western blot 
quantification values between different VEGFA isoforms and 
across developmental ages. Student’s t-test and a Dunnett 
test were used to compare area, thickness, and vascular den-
sity between control and treated organs. Differences in data 
were considered to be statistically significant at P < 0.05 un-
less otherwise stated. 
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